Glioblastoma is the most aggressive primary brain tumor with a poor prognosis. The 2021
WHO CNS5 classification has further stressed the importance of molecular signatures in
diagnosis although therapeutic breakthroughs are still lacking. In this review article, updates
on the current and novel therapies in IDH-wildtype GBM will be discussed.

Glioblastoma is an aggressive, often recalcitrant disease. In the majority of cases, prognosis
is dismal and current therapies only moderately prolong survival. Immunotherapy is
increasingly being recognized as an effective treatment modality. CD70 is a transmembrane
protein that shows restricted expression in tissue but has been described in various
malignancies. Therapeutic targeting of CD70 has demonstrated antitumor efficacy and is in
clinical trials. Here, we sought to characterize CD70 expression in a large cohort of gliomas …

Abstract O6-methylguanine DNA methyltransferase (MGMT) promoter methylation is an
important favorable predictive marker in patients with glioblastoma (GBM). We hypothesized
that MGMT status could be a surrogate marker of pretreatment tumor biology observed as
histopathological and radiological features. Apart from some radiological studies aiming to
noninvasively predict the MGMT status, few studies have investigated relationships between
MGMT status and phenotypical tumor biology. We have therefore aimed to investigate such …